Digital Day One

Hear cutting edge presentations delivered by AgenTus, Fate Therapeutics, NK Max America, FDA & Cytovia Therapeutics across 3 dedicated tracks to address:

  • The future for innate therapies – ask your questions during the Industry Leader’s Fireside Chat to hear the C-level leaders’ opinions on gene engineering, allogeneic drug development, solid tumors and future commercialization
  • Gene engineering strategies including CAR-NK and TRAIL variants to develop more resilient, persistence and targeted NK cells
  • Innovative process development to achieve scalable expansion for clinical manufacture
  • Regulatory perspectives on the development of innate immune cell products from CBER, FDA

And much more!

Key speakers include:

Daniel Teper

CEO

Cytovia Therapeutics

Evren Alici

CEO

Vycellix

Matthew Klinker

Biologist, Cell Therapy Branch, Division of Cellular and Gene Therapies

CBER

Xiaokui Zhang

CSO

Celularity

9:30 - 6:15 EDT | 6:30 - 3:15 PDT - All times are shown in EDT

9:30 am Online Registration & Virtual Coffee Networking

9:30 am Online Registration & Virtual Coffee Networking

9:50 am Chair’s Opening Remarks

9:50 am Chair’s Opening Remarks

10:00 am Industry Leader’s Fireside Chat

10:00 am Industry Leader’s Fireside Chat

Synopsis

An executive panel discussion from the C-level leaders of the NK space to set the scene on NK cell therapy development.

Ask your questions live to understand the expert’s thoughts on key topics including gene engineering, allogeneic drug development, optimal cell sources, driving clinical success in solid tumors and future thoughts on market access and commercialization.

11:00 am Robust Production of Potent CAR-NK Oncology with Poseida’s Non-Viral PiggyBac® and Cas-CLOVER™ Genetic Engineering Technologies

  • Stacey Cranert PhD Associate Director, Immuno-Oncology, Poseida Therapeutics

11:00 am Robust Production of Potent CAR-NK Oncology with Poseida’s Non-Viral PiggyBac® and Cas-CLOVER™ Genetic Engineering Technologies

  • Stacey Cranert PhD Associate Director, Immuno-Oncology, Poseida Therapeutics

Synopsis

  • Poseida’s non-viral gene editing technologies are efficient for genetic modification of natural killer cells
  • CAR gene addition with piggyBac and gene editing with Cas-CLOVER can be used in combination to produce target specific CAR-NK cells with specific gene knockouts
  • PiggyBac CAR-NK cells are highly cytotoxic and demonstrate antigen-specific targeting utilizing several different CAR constructs

11:30 am Enabling Clinical Grade CAR-NK Cell Manufacturing

11:30 am Enabling Clinical Grade CAR-NK Cell Manufacturing

Synopsis

  • Discover the tools to enable CAR NK cell translational research
  • Learn how the CliniMACS Prodigy® simplifies the manufacturing processes and enables the automated production of CAR NK cells
  • Optimized in-process and quality control for consistent cell manufacturing

12:00 pm Speed Networking

12:00 pm Speed Networking

12:30 pm Refreshment Break

12:30 pm Refreshment Break

1:35 pm Refreshment Break

1:35 pm Refreshment Break

2:20 pm Speaker Break Out Discussions

2:20 pm Speaker Break Out Discussions

3:50 pm Speaker Break Out Discussions

3:50 pm Speaker Break Out Discussions

4:10 pm Refreshment Break & Poster Session

4:10 pm Refreshment Break & Poster Session

4:50 pm Functional Single-Cell Proteomics: Uncovering Biomarkers of Persistence and Potency in Combination Immune Therapies

4:50 pm Functional Single-Cell Proteomics: Uncovering Biomarkers of Persistence and Potency in Combination Immune Therapies

5:20 pm Regulatory Perspectives on Development of Innate Immune Cell Products

  • Matthew Klinker Biologist, Cell Therapy Branch, Division of Cellular and Gene Therapies, CBER

5:20 pm Regulatory Perspectives on Development of Innate Immune Cell Products

  • Matthew Klinker Biologist, Cell Therapy Branch, Division of Cellular and Gene Therapies, CBER

Synopsis

  • Preparing for and submitting an investigational new drug application
  • Manufacturing considerations for early-stage studies
  • Product characterization considerations throughout development

5:45 pm Gene Editing to Enhance Function of iPSC-derived NK Cells

5:45 pm Gene Editing to Enhance Function of iPSC-derived NK Cells

Synopsis

  • Outline improved NK cell function via deletion of ADAM17
  • Combined CIS-deletion with other gene edits to improve NK cell activity
  • Reveal novel targets that regulate NK cell-mediated activity

6:10 pm Closing remarks

6:10 pm Closing remarks

6:15 pm End of Day 1

6:15 pm End of Day 1